HERON client summit produces clear connection between strong evidence and sound strategy
Recent meetings with a number of HERON’s global pharmaceutical and biotechnology clients were held to discuss the relationship between strong evidence and sound market access strategies. Reflecting on the import of both in the successful commercialization of new products, a number of clients cited internal organization as a potential obstacle to leveraging important evidence/information between product team members from HEOR to marketing, product commercialization, business development and other departments.
HERON supports commercial decision-making from early landscape assessment to pricing strategies and launch sequencing. In that capacity, we realize the productive gain from streamlined internal (product/portfolio team) communications and offer customized training and workshops geared to that end. Internal stakeholder reporting based on smart synthesis and predictable information flow are key and HERON is happy to discuss this process with interested parties.
HERON’s guide to strong evidence
The links below go to brief (3 minute) HERON webinar demonstrations on the role and import of evidence generation and synthesis, health economic modelling and data analytics, and global value dossiers, in the definition, substantiation and articulation of product value. HERON clients have found this information very useful as they engage us in early phase commercial planning:
- Evidence Review and Synthesis – Sam Stoddart, VP Scientific Affairs
- Economic Evaluation – Prof. John Posnett, SVP Health Economic Modelling Unit
- Global Value Dossiers – Dr. Ebony Samuels, VP Strategic Communications and Compliance
ISPOR Attendees Generate UN Food Donation
At ISPOR Madrid HERON experts were on hand to discuss, and deliver presentations on the ‘what, when and how’ of ‘Commercial Endpoints in Clinical Trial Design’, the latest instalment of HERON’s ‘Food For Thought’ webinar & presentation series on matters impacting the industry today. At ISPOR, HERON provided expert insight in the name of a good cause, with a donation made on behalf of all booth attendees to the United Nations’ World Food Programme.
With webinar recordings available online for presentations used to launch the Food For Thought platform in 2011 now available online, HERON are looking forward to expanding into Social Media and other venues in 2012, alongside a continued program of webinars and white papers.
A HERON Webinar 6 October: “Including Commercially-Focused Endpoints in Clinical Trials: Process and Benefits”
REGISTER NOW - participation is complimentary but limited.
45 minute webinar program, 15 minute Q&A
Commercially-focused end points in clinical trials have become a practical reality, if not a necessity, with reform-driven global health policies and worsening economic conditions strong drivers in the alignment of product effectiveness with clinical efficacy. Given these market conditions, the evidence-based articulation of product value has never been as important.
Join HERON experts for an insightful perspective on the process and benefits of determining market access and other commercially determined endpoints in clinical trials. We’ll explore the value-add of doing so and the potential consequence of not, along with step-by-step review of the ‘what, where, when, and how’ of integrating these endpoints successfully in a clinical and regulatory focused process.
HERON’s webinar will be supported by real-life case studies and will include:
- Why HERON recommends the inclusion of commercially-focused endpoints
- HERON’s experienced approach to the identification, validation, and refinement of strategic commercial endpoints and options:
- The benefits of starting early and/or starting now, with a process guide on optimizing access at any point in the development lifecycle
- The derived value of commercial endpoints:
- Questions & Answers
It is HERON’s observation that our pharmaceutical and biotechnology clients are proactively –and in some cases consequently – realigning their thinking and approach to commercial endpoints, including them earlier in the development life cycle and strengthening their evidence base to support intuitive pricing, reimbursement and access strategies and strong stakeholder communications. REGISTER NOW
ISPOR Madrid: Attend a short presentation at HERON’s booth and a donation will be made on your behalf to the UN Food Program
Attend a 10 minute presentation at HERON’s Booth on the ‘process and benefits of including market access and other commercially-focused endpoints in clinical trials’ and a donation will be made on your behalf to the United Nations World Food Program. Food for Thought is an initiative designed by HERON to foster relationships (and solutions) based on informed, collaborative thinking. It is also way for HERON and ISPOR attendees to give back.
HERON’s booth presentations will focus on the value-add of including commercial endpoints in clinical trials and the potential consequences of not – along with a review of the how, what, and when of integrating these endpoints successfully in a clinical and regulatory focused process.
PRESENTATION SCHEDULE: (Please CLICK HERE and we will send you an e-mail reminder prior to the presentations)
Why HERON recommends inclusion of commercially-focused endpoints:
Sunday, 6 November at 12:00 Monday, 7 November at 09:45
HERON’s approach to the identification, validation, and refinement of strategic commercial endpoints and options
Sunday, 6 November at 15:45 Monday, 7 November at 13:00
The benefits of starting early and/or starting now, with a process guide on optimizing access at any point in the development lifecycle.
Sunday, 6 November at 18:15 Monday, 7 November at 16:30
At ISPOR’s spring conference in Baltimore, HERON donated the equivalent of 3,100 meals which clearly pleased Rebecca Pon Keyser of the Maryland Food Bank (second from left in the photo above). LET’S DO IT AGAIN AT MADRID!
HERON Webinars on CER and VBP Available Here
With healthcare reform front and center on every continent and within every related governmental body, HERON’s exposure to and experience in HTA and non-HTA markets assures that science and strategy are aligned to generate the most positive outcomes for your healthcare products.
Barry Farrimond, Senior Vice President of HERON’s Evidence, Pricing & Access Group, Europe & Asia-Pacific, recently delivered a thought provoking webinar presentation, ‘Value Based Pricing, from theory to practice?’ which is available by clicking here.
HERON’s Thom Schoenwaelder, Vice President of Evidence, Pricing and Access, U.S., conducted a recent webinar titled: “Ready or Not: Strategic Considerations and Practical Implications of Comparative Effectiveness Research.” The event attracted over 100 registrants and spirited an interesting Q&A — available by clicking here .
Imperial College London Cites Dr. Min-Hua Jen of HERON
Researchers from the School of Public Health at Imperial College London and St George’s Healthcare NHS Trust recently released study findings showing that patients admitted to the hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile.
In a joint press release issued by Imperial College of London, available by clicking here, Dr. Min-Hua Jen was cited as first author of the study.